7-Benzyloxy-4-hydroxy-quinoline-3-carboxylic acid | 17825-22-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-Benzyloxy-4-hydroxy-quinoline-3-carboxylic acid
• 英文别名: 4-Hydroxy-7-benzyloxyquinoline-3-carboxylic acid；4-oxo-7-phenylmethoxy-1H-quinoline-3-carboxylic acid
• CAS: 17825-22-8
• 化学式: C₁₇H₁₃NO₄
• 分子量: 295.295
• InChiKey: ABQKYBVDVAXVNO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE<br/>[FR] AGENTS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES CARDIOVASCULAIRES ET INFLAMMATOIRES AYANT UNE STRUCTURE BASÉE SUR LA 4(1H)-QUINOLONE
  申请人：UCL BUSINESS PLC

  公开号：WO2015189560A1

  公开（公告）日：2015-12-17

  The present invention provides a compound of formula I, a tautomer thereof, or a pharmaceutically acceptable salt or N-oxide thereof for use in the treatment or prevention of a cardiovascular disease or of an inflammatory disease or condition:

  本发明提供了一种式I的化合物，其互变异构体，或其药用可接受的盐或N-氧化物，用于治疗或预防心血管疾病或炎症性疾病或症状。
• Agents for use in the treatment of cardiovascular and inflammatory diseases structurally based on 4(1 H)-quinolone
  申请人：UCL Business PLC

  公开号：US10087144B2

  公开（公告）日：2018-10-02

  The present invention provides a compound of formula I, a tautomer thereof, or a pharmaceutically acceptable salt or N-oxide thereof for use in the treatment or prevention of cardiovascular disease or of an inflammatory disease or condition: wherein: V is N or CR3; X is N or CR4; Y is N or CR5; Z is N or CR6; B is —(C═O)R1, a 5- to 10-membered heteroaryl group, or a group L′″-NRR′, wherein R and R′ are the same or different and each represents a hydrogen atom, a C1-C6 alkyl group or a C1-C6 haloalkyl group; R1 is a 5- to 10-membered heterocyclyl group, or —OR′, wherein R′ is a hydrogen atom, a C1-C6 alkyl group or a C1-C6 haloalkyl group, or R1 is a proteinogenic α amino acid, which is linked to the carbonyl moiety in the compound of formula (I) via the α amino group, which amino acid is optionally esterified at the α carboxylic acid group with a C1-C6 alkyl group or a C6-C10 aryl group, or R1 is —NR″R′″, —NRIV-L′″-CONR″R′″, or —NRIV-L′″-COOR, wherein R, R″, R′″ and RIV are the same or different and each represents a hydrogen atom, a C1-C6 alkyl group or a C1-C6 haloalkyl group; either (a) W is N and R9 and R2 together form a bond, or (b) W is CR8, R8 and R9 together form a bond and R2 is a hydrogen atom, or a C1-C6 alkyl, C1-C6 haloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, 5- to 10-membered heterocyclyl, -L′-A2, C3-C10 cycloalkyl, or —COOR′ group, wherein R′ is a hydrogen atom or C1-C6 alkyl group, or, when Z is a moiety CR6, R2 may form, together with R6 and the carbon and nitrogen atoms which connect R2 and R6 in the formula (I), a 5- to 6-membered heterocyclic ring; R3 is a hydrogen atom, a halogen atom, or a hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, nitro, or —NR′R″ group, wherein R′ and R″ are the same or different and each represent a hydrogen atom or C1-C6 alkyl group; R4 and R5 are the same or different and each represent a hydrogen atom, a halogen atom, or a hydroxyl, C1-C8 alkyl, C1-C8 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, nitro, —NR′R″, —CO2R′″, C6-C10 aryl, 5- to 10-membered heteroaryl, 5 to 10-membered heterocyclyl, or —CO—(C1-C6 alkyl) group, wherein R′, R″ and R′″ are the same or different and each represent a hydrogen atom or C1-C6 alkyl group, or R4 and R5 and the carbon atoms bonded to R4 and R5 together form a 5- to 6-membered heterocyclic ring; R6 is a hydrogen atom, a halogen atom, or a C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy or —CO2R′ group, wherein R′ is hydrogen or C1-C6 alkyl, or, when W is a moiety CR8, R6 may form, together with R2 and the carbon and nitrogen atoms which connect R6 and R2 in the formula (I), a 5- to 6-membered heterocyclic ring; R7 is a hydrogen atom, a halogen atom, or a C1-C6 alkyl, or C1-C6 haloalkyl group, A2 represents a C6-C10 aryl or 5- to 10-membered heteroaryl group; L′, and L′″ are the same or different and each represent a C1-C6 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene group; said aryl, heteroaryl, cycloalkyl and heterocyclyl groups being unsubstituted or substituted with one or more substituents selected from halogen, hydroxy, C1-C4 alkyl, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, —SOR, —SO2R, —NR′R″, —NR′(C═O)R″, —COOR, nitro and cyano substituents, wherein R, R′ and R″ are the same or different and each represents a hydrogen atom or C1-C4 alkyl group.

  本发明提供了一种式 I 的化合物、其同系物或其药学上可接受的盐或 N-氧化物，用于治疗或预防心血管疾病或炎症性疾病或病症： 其中： V 是 N 或 CR3 X 是 N 或 CR4 Y 是 N 或 CR5 Z 是 N 或 CR6； B 是-(C═O)R1、5 至 10 元杂芳基或一个基团 L′″-NRR′，其中R和R′相同或不同，各自代表氢原子、C1-C6烷基或C1-C6卤代烷基； R1 是 5 至 10 元杂环基，或 -OR′，其中 R′是氢原子、C1-C6 烷基或 C1-C6 卤代烷基，或 R1 是蛋白源 α 氨基酸，它通过 α 氨基与式（I）化合物中的羰基相连、R1是-NR″R′″、-NRIV-L′″-CONR″R′″或-NRIV-L′″-COOR，其中R、R″、R′″和RIV相同或不同，各自代表氢原子、C1-C6烷基或C1-C6卤代烷基； 或者 (a) W 是 N，R9 和 R2 一起形成键，或者 (b) W 是 CR8，R8 和 R9 一起形成键，R2 是氢原子，或者是 C1-C6 烷基、C1-C6 卤代烷基、C6-C10 芳基、5-至 10 元杂芳基、5-至 10 元杂环烷基、-L′-A2、C3-C10 环烷基、或-COOR′基团，其中 R′为氢原子或 C1-C6 烷基，或者当 Z 为 CR6 子团时，R2 可与 R6 以及连接式（I）中 R2 和 R6 的碳原子和氮原子一起形成 5 至 6 元杂环； R3 是氢原子、卤素原子或羟基、C1-C6 烷基、C1-C6 烷氧基、C1-C6 卤代烷基、C1-C6 卤代烷氧基、硝基或 -NR′R″ 基团，其中 R′ 和 R″ 相同或不同，且各自代表氢原子或 C1-C6 烷基； R4 和 R5 相同或不同，各自代表氢原子、卤素原子或羟基、C1-C8 烷基、C1-C8 卤代烷基、C1-C6 烷氧基、C1-C6 卤代烷氧基、硝基、-NR′R″、-CO2R′″、C6-C10 芳基、5-至 10 元杂芳基、5-至 10 元杂环基、或-CO-(C1-C6 烷基)基团，其中 R′、R″ 和 R′″ 相同或不同，且各自代表氢原子或 C1-C6 烷基，或 R4 和 R5 以及与 R4 和 R5 键合的碳原子共同形成 5 至 6 元杂环； R6 是氢原子、卤素原子或 C1-C6 烷基、C1-C6 卤代烷基、C1-C6 烷氧基、C1-C6 卤代烷氧基或 -CO2R′ 基团，其中 R′ 是氢或 C1-C6 烷基，或者当 W 是分子 CR8 时，R6 可与式 (I) 中的 R2 以及连接 R6 和 R2 的碳原子和氮原子一起形成 5 至 6 元杂环； R7 是氢原子、卤素原子或 C1-C6 烷基或 C1-C6 卤代烷基、 A2 代表 C6-C10 芳基或 5 至 10 元杂芳基； L′和 L′″相同或不同，各自代表 C1-C6 烯基、C2-C6 烯基或 C2-C6 炔基； C1-C4卤代烷基、C1-C4卤代烷氧基、-SOR、-SO2R、-NR′R″、-NR′(C═O)R″、-COOR、硝基和氰基取代基，其中 R、R′和 R″ 相同或不同，各自代表氢原子或 C1-C4 烷基。
• AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE
  申请人：UCL Business PLC

  公开号：EP3145914A1

  公开（公告）日：2017-03-29